APC anti-human IL-13 Antibody -上海雅吉生物科技有限公司

规格	价格	库存
50µg	￥ 2064	1

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

COS-expressed, recombinant human IL-13

Formulation

test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

?g sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser

Red Laser (633 nm)

Application Notes

ELISA or ELISPOT Capture^1,2: The Ultra-LEAF? Purified JES10-5A2 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5020 antibody (Cat. No. 502001) as the detecting antibody. The Ultra-LEAF? Purified antibody is suggested for ELISPOT capture.

Application References (PubMed link indicates BioLegend citation)

McKenzie, A., et al. 1994. Curr. Prot. Immunol.. John Wiley & Sons. New York. Section 6.18.
Abrams, J. 1995. Curr. Prot. Immunol.. John Wiley and Sons, New York. Unit 6.20.
Schaerli, P., et al. 2000. J. Exp. Med. 192:1553.
Andersson, J., et al. 1994. Immunology 83:16.
Skansen-Saphir, U., et al. 1994. Eur. J. Immunol. 24:916.
Andersson, U., et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
Gelfand, E. W., et al. 2006. J. Aller. and Clinic. Immunol. 117:577.
Knorr, C., et al. 1999. Am. J. Pathol. 155:2019.

Product Citations

Neunkirchner A, et al. 2011. J Immunol. 187:4077. PubMed
Chen L et al. 2018. Immunity. 49(3):464-476 . PubMed
Arif S, et al. 2020. Diabetologia. 63(6):1186-1198.. PubMed
Huber J, et al. 2010. J Immunol. 185:813. PubMed
Yang R, et al. 2020. Cell. 183(7):1826-1847.e31. PubMed
Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
Yu KK, et al. 2021. JCI Insight. 6:. PubMed
Bal S, et al. 2016. Nat Immunol. 10.1038/ni.3444. PubMed
Barber J, et al. 2013. Proc Natl Acad Sci U S A. 110:8164. PubMed

RRID

AB_315203 (BioLegend Cat. No. 501908) AB_315202 (BioLegend Cat. No. 501907)

Antigen Details

Structure: Cytokine; 17 kD (Mammalian)
Bioactivity: Suppression of macrophage cytotoxic activity; upregulation of IL-1RA expression; suppression of IL-1, IL-6, IL-8, IL-10, IL-12, chemokines MCP, MIP-1; differentiation of B cells, monocytes
Cell Sources: Activated T cells, mast cells, NK cells
Cell Targets: B cells, monocytes, macrophages, basophils
Receptors: Moderate affinity IL-13Rα1; high affinity heterodimer IL-13Rα1/IL-4Rα also binds IL-4; both receptor complexes have γ-subunit in common with IL-2R, IL-4R, IL-7R, IL-15R ; high affinity IL-13Rα2 incapable of signaling
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hilton, D., et al. 1996. P. Natl. Acad. Sci. USA 93:497.
3. Obiri, N., et al. 1995. J. Biol. Chem. 270:8797.
4. Ochensberger, B., et al. 1996. Blood 88:3028.
Regulation: IL-13Rα2 possible antagonist
Gene ID: 3596 View all products for this Gene ID
UniProt: View information about IL-13 on UniProt.org

上海细胞库

原代细胞

细胞培养

细胞服务

酶联试剂盒

生化试剂盒

PCR试剂盒

抗体蛋白

试剂耗材

首页 > 抗体蛋白 > 抗体

产品详情

Product Details

Antigen Details

联系我们